October 2024
1. CASTELEIN S, Visser E, Brilman MF, Wardenaar KJ, et al
   Identifying factors strongest associated with clinical, societal and personal recovery in people with psychosis with a long duration of illness.
   Compr Psychiatry. 2024;136:152540.
   

   >> Share

   
   July 2024
2. SHI X, Sun X, Zhang C, Li Z, et al
   Individual stigma in people with severe mental illness: Associations with public stigma, psychological capital, cognitive appraisal and coping orientations.
   Compr Psychiatry. 2024;132:152474.
   

   >> Share

   
   May 2024
3. REDLICH BOSSY M, Muller DR, Niedermoser DW, Burrer A, et al
   Impact of psychopathology on day-to-day living in patients with schizophrenia: A network analysis.
   Compr Psychiatry. 2024;133:152501.
   

   >> Share

   
   
4. DE FILIPPIS R, Aloi M, Liuzza MT, Pugliese V, et al
   Aberrant salience mediates the interplay between emotional abuse and positive symptoms in schizophrenia.
   Compr Psychiatry. 2024;133:152496.
   

   >> Share

   
   March 2024
5. SAELE RH, Ndetei DM, Mutiso VN, Mamah D, et al
   Epidemiology of DSM-5 psychiatric disorders in Kenyan Youth with Low and High Psychosis Risk.
   Compr Psychiatry. 2024;131:152473.
   

   >> Share

   
   February 2024
6. ANDREO-JOVER J, Wootton O, Fernandez-Jimenez E, Munoz-Sanjose A, et al
   Adverse childhood experiences and cognition: A cross-sectional study in Xhosa people living with schizophrenia and matched medical controls.
   Compr Psychiatry. 2024;130:152459.
   

   >> Share

   
   January 2024
7. ANDREA S, Jan K, Antonin S, Lea J, et al
   Time is the enemy: Negative symptoms are related to even slight differences in the duration of untreated psychosis.
   Compr Psychiatry. 2024;130:152450.
   

   >> Share

   
   December 2023
8. FELSENHEIMER A, Rapp AM
   Proverb comprehension in schizophrenia: A comprehensive review and meta-analysis.
   Compr Psychiatry. 2023;129:152444.
   

   >> Share

   
   November 2023
9. WOLPE N, Vituri A, Jones PB, Shahar M, et al
   The longitudinal structure of negative symptoms in treatment resistant schizophrenia.
   Compr Psychiatry. 2023;128:152440.
   

   >> Share

   
   September 2023
10. SAMI M, Liddle P
    Neurobiology of psychosis and schizophrenia 2022: Nottingham meeting.
    Compr Psychiatry. 2023;127:152415.
    

    >> Share

    
    
11. DIDIER PR, Moore TM, Calkins ME, Prettyman G, et al
    Evaluation of a new intrinsic and extrinsic motivation scale in youth with psychosis spectrum symptoms.
    Compr Psychiatry. 2023;127:152413.
    

    >> Share

    
    July 2023
12. MOHN-HAUGEN CR, Moller P, Mohn C, Laroi F, et al
    Anomalous self-experiences and neurocognitive functioning in adolescents at risk for psychosis: Still no significant associations found between these two vulnerability markers.
    Compr Psychiatry. 2023;125:152400.
    

    >> Share

    
    May 2023
13. ZHENG Y, Li Q, Gong B, Xia Y, et al
    Negative-emotion-induced reduction in speech-in-noise recognition is associated with source-monitoring deficits and psychiatric symptoms in mandarin-speaking patients with schizophrenia.
    Compr Psychiatry. 2023;124:152395.
    

    >> Share

    
    
14. VASKINN A, Engelstad KN, Zamparini M, de Girolamo G, et al
    The "zipper model of empathy" applied to violence in schizophrenia: A search for social cognitive underpinnings of lack of empathic behavior.
    Compr Psychiatry. 2023;124:152391.
    

    >> Share

    
    March 2023
15. MISIAK B, Frydecka D, Kowalski K, Samochowiec J, et al
    Associations of neurodevelopmental risk factors with psychosis proneness: Findings from a non-clinical sample of young adults.
    Compr Psychiatry. 2023;123:152385.
    

    >> Share

    
    January 2023
16. CAO Y, Ji S, Chen Y, Zhang X, et al
    Association between autoimmune diseases of the nervous system and schizophrenia: A systematic review and meta-analysis of cohort studies.
    Compr Psychiatry. 2023;122:152370.
    

    >> Share

    
    
17. YAN H, Huang Z, Lu Y, Qiu Y, et al
    Associations between metabolic disorders and sleep disturbance in patients with schizophrenia.
    Compr Psychiatry. 2023;122:152369.
    

    >> Share

    
    October 2022
18. VASS E, Simon V, Csukly G, Fekete Z, et al
    Virtual reality-based theory of mind intervention in schizophrenia: Preliminary efficacy results.
    Compr Psychiatry. 2022;119:152350.
    

    >> Share

    
    
19. RODRIGUEZ-TESTAL JF, Fuentes-Marquez S, Senin-Calderon C, Fernandez-Leon S, et al
    Validation of the aberrant salience inventory in a general and clinical Spanish population.
    Compr Psychiatry. 2022;118:152343.
    

    >> Share

    
    July 2022
20. BIEDERMANN F, Kurzthaler I, Haibach M, Pardeller S, et al
    Driving fitness in clinically stable outpatients with chronic schizophrenia.
    Compr Psychiatry. 2022;118:152340.
    

    >> Share

    
    
21. RAJENDRAN P, Van Winssen C, Viswasam K, Tariq N, et al
    The psychometric properties of the Nepean Belief Scale as a tool for assessing delusions in schizophrenia and related psychotic disorders.
    Compr Psychiatry. 2022;117:152337.
    

    >> Share

    
    May 2022
22. WIDING L, Simonsen C, Flaaten CB, Haatveit B, et al
    Premorbid characteristics of patients with DSM-IV psychotic disorders.
    Compr Psychiatry. 2022;115:152310.
    

    >> Share

    
    March 2022
23. NADESALINGAM N, Chapellier V, Lefebvre S, Pavlidou A, et al
    Motor abnormalities are associated with poor social and functional outcomes in schizophrenia.
    Compr Psychiatry. 2022;115:152307.
    

    >> Share

    
    
24. GE F, Huo Z, Liu Y, Du X, et al
    Association between schizophrenia and prostate cancer risk: Results from a pool of cohort studies and Mendelian randomization analysis.
    Compr Psychiatry. 2022;115:152308.
    

    >> Share

    
    February 2022
25. JAYA ES, Pillny M, Lincoln TM, Riehle M, et al
    Does social defeat cause negative symptoms? A prospective study in a multi-national community sample.
    Compr Psychiatry. 2022;113:152289.
    

    >> Share

    
    November 2021
26. DORFLINGER C, LeHew C, Carey H, Roche-Desilets J, et al
    Effectiveness of paliperidone palmitate one-month long-acting injection in obese vs. non-obese patients.
    Compr Psychiatry. 2021;111:152269.
    

    >> Share

    
    October 2021
27. AISSA A, Jouini R, Ouali U, Zgueb Y, et al
    Clinical predictors of response to clozapine in Tunisian patients with treatment resistant schizophrenia.
    Compr Psychiatry. 2021;112:152280.
    

    >> Share

    
    July 2021
28. HE XY, Hou CL, Huang ZH, Huang YH, et al
    Individuals at ultra-high risk of psychosis and first-degree relatives of patients with schizophreniaexperience impaired family functionality and social support deficit in comparison to healthy controls.
    Compr Psychiatry. 2021;109:152263.
    

    >> Share

    
    
29. NAVARRA-VENTURA G, Vicent-Gil M, Serra-Blasco M, Massons C, et al
    Group and sex differences in social cognition in bipolar disorder, schizophrenia/schizoaffective disorder and healthy people.
    Compr Psychiatry. 2021;109:152258.
    

    >> Share

    
    June 2021
30. MEDIAVILLA R, Lopez-Arroyo M, Gomez-Arnau J, Wiesepape C, et al
    Autobiographical memory in schizophrenia: The role of metacognition.
    Compr Psychiatry. 2021;109:152254.
    

    >> Share

    
    April 2021
31. PARK HY, Seo E, Park KM, Koo SJ, et al
    Shame and guilt in youth at ultra-high risk for psychosis.
    Compr Psychiatry. 2021;108:152241.
    

    >> Share

    
    
32. VEGA D, Acosta FJ, Saavedra P
    Nonadherence after hospital discharge in patients with schizophrenia or schizoaffective disorder: A six-month naturalistic follow-up study.
    Compr Psychiatry. 2021;108:152240.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share